Early Response As a Predictor of Long-Term Remission in DMARD-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate

被引：0
|
作者：
Weinblatt, Michael [1 ]
Bingham, Clifton [2 ]
Burmester, Gerd [3 ]
Bykerk, V. P. [4 ]
Furst, Daniel E. [5 ]
Mariette, Xavier [6 ]
van der Heijde, Desiree [7 ]
Tatla, Daljit [8 ]
Arendt, Catherine [9 ]
Mountian, Irina [10 ]
VanLunen, Brenda [8 ]
Emery, Paul [11 ]
机构：
[1] Brigham & Womens Hosp, Rheumatol Immunol & Allergy, Boston, MA 02115 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Charite, Dept Rheumatol & Clin Immunol, D-13353 Berlin, Germany
[4] Hosp Special Surg, New York, NY 10021 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA
[6] Univ Paris Sud, Hop Univ Paris Sud, AP HP, Paris, France
[7] Univ Hosp, Maastricht, Netherlands
[8] UCB Pharma, Raleigh, NC USA
[9] UCB Pharma, Global Med Affairs, Brussels, Belgium
[10] UCB Pharma, Brussels, Belgium
[11] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1638
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
    Mease, Philip
    Fleischmann, Roy
    Davies, Owen
    Nurminen, Tommi
    van der Heijde, Desiree
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S685 - S685
  • [32] The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
    Rannio, Tuomas
    Asikainen, Juha
    Hannonen, Pekka
    Yli-Kerttula, Timo
    Ekman, Paivi
    Kuusalo, Laura
    Pirila, Laura
    Mali, Markku
    Puurtinen-Vilkki, Marja
    Kortelainen, Satu
    Paltta, Johanna
    Taimen, Kirsi
    Kauppi, Markku J.
    Laiho, Kari
    Nyrhinen, Satu
    Makinen, Heidi
    Isomaki, Pia
    Uotila, Terhi
    Aaltonen, Kalle
    Kautiainen, Hannu
    Sokka-Isler, Tuulikki
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [33] DISEASE ACTIVITY AND CLINICAL RESPONSE EARLY IN THE COURSE OF TREATMENT PREDICT LONG-TERM OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
    Mease, P. J.
    Fleischmann, R.
    Davies, O.
    Nurminen, T.
    van der Heijde, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 741 - 741
  • [34] DAS28 (ESR) Response at Week 12 is Predictive of Long-Term Disease Activity in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
    Schiff, Michael
    Keystone, Edward
    Kvien, Tore
    Curtis, Jeffrey
    Emery, Paul
    Luijtens, Kristel
    Choy, Ernest
    [J]. JOURNAL OF RHEUMATOLOGY, 2010, 37 (06) : 1332 - 1332
  • [35] Long-Term (4-Year) Efficacy and Safety of Apremilast Monotherapy in DMARD-Naive Subjects with Active Psoriatic Arthritis
    Wells, Alvin F.
    Edwards, Christopher J.
    Kivitz, Alan J.
    Bird, Paul
    Nguyen, Dianne
    Paris, Maria
    Teng, Lichen
    Aelion, Jacob A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [36] LONG-TERM (5-YEAR) EFFICACY AND SAFETY OF APREMILAST MONOTHERAPY IN DMARD-NAIVE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Wells, A. F.
    Edwards, C. J.
    Kivitz, A. J.
    Bird, P.
    Guerette, B.
    Delev, N.
    Paris, M.
    Teng, L.
    Aelion, J. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1576 - 1577
  • [37] Early Remission Status As a Predictor of Long-Term Outcome in Crohn's Disease Patients Treated With Certolizumab Pegol: Results of an Analysis From the PRECiSE 3 Study
    Melmed, Gil
    McGovern, Dermot
    Schreiber, Stefan
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S252 - S252
  • [38] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
    Emery, P.
    Bingham, C. O.
    Burmester, G. -R.
    Bykerk, V. P.
    Furst, D. E.
    Mariette, X.
    Purcaru, O.
    Coteur, G.
    VanLunen, B.
    Weinblatt, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 712 - 713
  • [39] THREE OUT OF EVERY FOUR PATIENTS WITH DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS MEET DAS28 REMISSION AT 12 MONTHS IN FINLAND
    Rannio, T.
    Asikainen, J.
    Hannonen, P.
    Yli-Kerttula, T.
    Ekman, P.
    Pirila, L.
    Kuusalo, L.
    Mali, M.
    Puurtinen-Vilkki, M.
    Kortelainen, S.
    Paltta, J.
    Taimen, K.
    Kauppi, M.
    Laiho, K.
    Nyrhinen, S.
    Makinen, H.
    Isomaki, P.
    Uotila, T.
    Aaltonen, K.
    Kautiainen, H.
    Sokka, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 697 - 698
  • [40] Certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in patients with active rheumatoid arthritis: Results from the rapid 1 study
    Bykerk, Vivian
    Mason, David
    Keystone, Edward
    [J]. JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1202 - 1202
12345